M.E. Gleave

511 total citations
22 papers, 413 citations indexed

About

M.E. Gleave is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, M.E. Gleave has authored 22 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in M.E. Gleave's work include Prostate Cancer Treatment and Research (5 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). M.E. Gleave is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). M.E. Gleave collaborates with scholars based in Canada, United States and India. M.E. Gleave's co-authors include Fred Saad, L.R. Bégin, Anne‐Marie Mes‐Masson, Laurent Lessard, Paul S. Rennie, Martin G. McLoughlin, Hideaki Miyake, Kim Chi, Lorne D. Sullivan and S. Larry Goldenberg and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and British Journal of Cancer.

In The Last Decade

M.E. Gleave

22 papers receiving 402 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.E. Gleave Canada 8 183 172 137 117 51 22 413
Chenfei Chi China 14 287 1.6× 168 1.0× 177 1.3× 168 1.4× 18 0.4× 26 489
Kyrillus S. Shohdy Egypt 12 213 1.2× 88 0.5× 197 1.4× 114 1.0× 26 0.5× 39 440
Tahir Qayyum United Kingdom 11 116 0.6× 137 0.8× 144 1.1× 93 0.8× 53 1.0× 20 386
W. P. Peelen Netherlands 9 212 1.2× 150 0.9× 62 0.5× 85 0.7× 38 0.7× 14 400
P. Athanassiades Greece 12 93 0.5× 179 1.0× 139 1.0× 71 0.6× 20 0.4× 47 470
Curtis Dunshee United States 11 424 2.3× 107 0.6× 225 1.6× 130 1.1× 18 0.4× 41 548
Valentina Tateo Italy 10 150 0.8× 114 0.7× 205 1.5× 96 0.8× 44 0.9× 36 437
Yuancheng Gou China 12 108 0.6× 130 0.8× 141 1.0× 64 0.5× 31 0.6× 16 395
Hironori Betsunoh Japan 11 112 0.6× 153 0.9× 103 0.8× 70 0.6× 23 0.5× 24 362
Dmitry S. Mikhaylenko Russia 10 63 0.3× 167 1.0× 80 0.6× 86 0.7× 45 0.9× 43 369

Countries citing papers authored by M.E. Gleave

Since Specialization
Citations

This map shows the geographic impact of M.E. Gleave's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.E. Gleave with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.E. Gleave more than expected).

Fields of papers citing papers by M.E. Gleave

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.E. Gleave. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.E. Gleave. The network helps show where M.E. Gleave may publish in the future.

Co-authorship network of co-authors of M.E. Gleave

This figure shows the co-authorship network connecting the top 25 collaborators of M.E. Gleave. A scholar is included among the top collaborators of M.E. Gleave based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.E. Gleave. M.E. Gleave is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Frees, Sebastian, Claudia Chávez‐Muñoz, Bin‐Bing S. Zhou, et al.. (2017). Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo. European Urology Supplements. 16(3). e1480–e1480. 1 indexed citations
2.
3.
Lo, Andrea, Calum MacAulay, Mira Keyes, et al.. (2015). Evaluation of a Novel Quantitative Digital Pathology Technique as a Tool for Predicting Prostate Cancer Recurrence. International Journal of Radiation Oncology*Biology*Physics. 93(3). E223–E223. 2 indexed citations
4.
Nelson, James B., Karim Fizazi, Kathy D. Miller, et al.. (2011). Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 29(7_suppl). 117–117. 20 indexed citations
5.
Gleave, M.E., S. Larry Goldenberg, Alan So, et al.. (2010). A phase II study of preoperative figitumumab (F) in patients (pts) with localized prostate cancer (PCa).. Journal of Clinical Oncology. 28(15_suppl). 4662–4662. 4 indexed citations
6.
Mugabe, Clement, Alan So, Rajesh K. Kainthan, et al.. (2009). 306 MUCOADHESIVE PACLITAXEL FOR INTRAVESICAL BLADDER CANCER THERAPY. European Urology Supplements. 8(4). 197–197. 1 indexed citations
7.
8.
Yu, Dawei, Wenzhuo Jia, Arrigo De Benedetti, et al.. (2005). Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. Cancer Gene Therapy. 13(1). 32–43. 23 indexed citations
9.
Lessard, Laurent, L.R. Bégin, M.E. Gleave, Anne‐Marie Mes‐Masson, & Fred Saad. (2005). Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. British Journal of Cancer. 93(9). 1019–1023. 122 indexed citations
10.
Andriole, Gerald L., Peter A. Humphrey, Paul S. Ray, et al.. (2005). RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER. The Journal of Urology. 173(4). 1433–1434. 2 indexed citations
11.
Gleave, M.E., K. N., Larry Goldenberg, et al.. (2004). Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a). Journal of Clinical Oncology. 22(14_suppl). 4635–4635. 3 indexed citations
12.
13.
14.
Elhilali, M., M.E. Gleave, Yves Fradet, et al.. (2000). Placebo‐associated remissions in a multicentre, randomized, double‐blind trial of interferon γ‐1b for the treatment of metastatic renal cell carcinoma. British Journal of Urology. 86(6). 613–618. 39 indexed citations
15.
Bruchovsky, Nicholas, Marianne D. Sadar, John M. Crook, et al.. (2000). Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.. PubMed. 4(3). 191–9;discussion 201. 65 indexed citations
16.
Gleave, M.E., M. Elhilali, Yves Fradet, et al.. (1999). Interferon Gamma-1b Compared With Placebo in Metastatic Renal-Cell Carcinoma. The Journal of Urology. 161(5). 1736–1737. 12 indexed citations
17.
Sullivan, Lorne D., et al.. (1999). Early experience with transurethral needle ablation of large prostates.. PubMed. 6(1). 686–691. 5 indexed citations
18.
19.
Sullivan, Lorne D., et al.. (1997). Early experience with high‐intensity focused ultrasound for the treatment of benign prostatic hypertrophy. British Journal of Urology. 79(2). 172–176. 36 indexed citations
20.
Gleave, M.E., et al.. (1989). Meatal-based tubularized skin flap for distal hypospadias repair.. PubMed. 32(3). 150–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chenfei Chi Breakdown of academic impact, for papers by Kyrillus S. Shohdy Breakdown of academic impact, for papers by Tahir Qayyum Breakdown of academic impact, for papers by W. P. Peelen Breakdown of academic impact, for papers by P. Athanassiades Breakdown of academic impact, for papers by Curtis Dunshee Breakdown of academic impact, for papers by Valentina Tateo Breakdown of academic impact, for papers by Yuancheng Gou Breakdown of academic impact, for papers by Hironori Betsunoh Breakdown of academic impact, for papers by Dmitry S. Mikhaylenko
Rankless by CCL
2026